Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Lexaria Bioscience Corp. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q4 2021
- Shares held
- 472.6K
- +17.9K (+3.9%) vs. Q4 2021
- Total value
- $1.41M
- −$430.0K (−23.4%) vs. Q4 2021
- New holders
- 2
- 3 more added
- Sold out
- 2
- 1 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gables Capital Management Inc. | 13 | $0 | 0.00% | 00.0% | Unchanged |
| Aspire Private Capital, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 394 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,030 | $3.00K | 0.00% | +5+0.5% | Added |
| Advisor Group Holdings, Inc. | 2,043 | $7.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,663 | $9.00K | 0.00% | −1,471−35.6% | Reduced |
| 1832 Asset Management L.P. | 2,686 | $9.00K | 0.00% | +2,686 | New |
| Tower Research Capital LLC (TRC) | 3,056 | $10.0K | 0.00% | +1,852+153.8% | Added |
| Virtu Financial LLC | 12,026 | $40.0K | 0.00% | +12,026 | New |
| Vanguard Group Inc | 34,122 | $112.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 49,002 | $161.0K | 0.00% | 00.0% | Unchanged |
| Invenomic Capital Management LP | 365,212 | $1.06M | 0.15% | +6,099+1.7% | Added |
| Edge Wealth Management LLC | 0 | $0 | 0.00% | −3,333−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| MD Financial Management Inc. | – | – | – | – | Not filed |